Quick Answer
TANDEM DIABETES CARE INC reported Total Revenue of $1.01 billion for fiscal year 2025.
TANDEM DIABETES CARE INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.01B +7.9% |
$940.20M +25.7% |
$747.72M -6.7% |
$801.22M +14.0% |
$702.80M +40.9% |
$498.83M +37.7% |
| Revenue (ASC 606) | $1.01B +7.9% |
$940.20M +25.7% |
$747.72M -6.7% |
$801.22M +14.0% |
$702.80M +40.9% |
$498.83M +37.7% |
| Net Income | -$204.71M -113.2% |
-$96.03M +56.9% |
-$222.61M -135.3% |
-$94.59M -707.7% |
$15.57M +145.3% |
-$34.38M -38.9% |
| Diluted EPS | -$3.04 -106.8% |
-$1.47 +57.1% |
-$3.43 -133.3% |
-$1.47 -712.5% |
$0.24 +142.9% |
-$0.56 -33.3% |
| Total Assets | $881.11M -8.9% |
$967.66M +1.6% |
$952.66M -9.5% |
$1.05B +16.3% |
$905.14M +26.3% |
$716.41M +119.7% |
| Cash and Equivalents | $90.63M +30.9% |
$69.23M +17.6% |
$58.87M -65.9% |
$172.52M +142.4% |
$71.18M -24.8% |
$94.61M +84.9% |
| Stockholders Equity | $155.17M -41.0% |
$263.10M -16.1% |
$313.63M -28.7% |
$439.95M +1.6% |
$433.11M +18.2% |
$366.31M +87.9% |
| R&D Expense | — | — | — | — | $92.05M +44.8% |
$63.57M +40.7% |
| Operating Income | -$187.26M -88.9% |
-$99.13M +57.5% |
-$233.23M -151.2% |
-$92.85M -509.9% |
$22.65M +384.7% |
-$7.96M +52.4% |
| Gross Profit | $546.01M +11.5% |
$489.57M +33.1% |
$367.69M -11.0% |
$412.99M +9.8% |
$376.21M +44.4% |
$260.52M +34.1% |
| Shares Outstanding | 68.29M +3.1% |
66.26M +1.1% |
65.55M +1.6% |
64.51M +1.1% |
63.83M +2.4% |
62.34M +4.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $249.25M | +2.2% | +3.6% |
| Revenue (ASC 606) | September 30, 2025 | $249.25M | +2.2% | +3.6% |
| Net Income | September 30, 2025 | -$21.16M | +9.0% | +59.6% |
| Diluted EPS | September 30, 2025 | -$0.31 | +11.4% | +60.3% |
| Total Assets | September 30, 2025 | $874.65M | -8.7% | -0.1% |
| Cash and Equivalents | September 30, 2025 | $91.95M | +87.5% | +43.4% |
| Stockholders Equity | September 30, 2025 | $132.97M | -44.1% | -0.2% |
| R&D Expense | June 30, 2022 | $33.57M | +63.8% | +1.2% |
| Operating Income | September 30, 2025 | -$22.86M | +12.4% | +55.9% |
| Gross Profit | September 30, 2025 | $134.29M | +7.7% | +6.7% |
| Shares Outstanding | September 30, 2025 | 67.77M | +3.2% | +0.4% |
- TANDEM DIABETES CARE INC reported Total Revenue of $1.01 billion for fiscal year 2025.
- TANDEM DIABETES CARE INC showed an increase of +7.9% in Total Revenue compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Revenue (ASC 606) of $1.01 billion for fiscal year 2025.
- TANDEM DIABETES CARE INC showed an increase of +7.9% in Revenue (ASC 606) compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Net Income of -$204.71 million for fiscal year 2025.
- TANDEM DIABETES CARE INC showed a decrease of -113.2% in Net Income compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Diluted EPS of $3.04 per share (loss) for fiscal year 2025.
- TANDEM DIABETES CARE INC showed a decrease of -106.8% in Diluted EPS compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Total Assets of $881.11 million for fiscal year 2025.
- TANDEM DIABETES CARE INC showed a decrease of -8.9% in Total Assets compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Cash and Equivalents of $90.63 million for fiscal year 2025.
- TANDEM DIABETES CARE INC showed an increase of +30.9% in Cash and Equivalents compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Stockholders Equity of $155.17 million for fiscal year 2025.
- TANDEM DIABETES CARE INC showed a decrease of -41.0% in Stockholders Equity compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported R&D Expense of $92.05 million for fiscal year 2021.
- TANDEM DIABETES CARE INC showed an increase of +44.8% in R&D Expense compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Operating Income of -$187.26 million for fiscal year 2025.
- TANDEM DIABETES CARE INC showed a decrease of -88.9% in Operating Income compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Gross Profit of $546.01 million for fiscal year 2025.
- TANDEM DIABETES CARE INC showed an increase of +11.5% in Gross Profit compared to the prior fiscal year.
- TANDEM DIABETES CARE INC reported Shares Outstanding of 68.29 million shares for fiscal year 2025.
- TANDEM DIABETES CARE INC showed an increase of +3.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: